						Stage	Stage 1 discovery (<i>n</i> = 63,926)	=63,926)	Stage	Stage 2 ($n = 18,845$)		Overal	Stage 1+Stag	Overall Stage $1 + \text{Stage 2}$ ($n = 82,771$)	6
Variantª	Chr.	Position ^b	Closest gene ^c	Major/ minor alleles	MAF	S.	95% CI	٩	8	95% CI ^e	م	OR	95% CI	Meta P	l² (%), Pí
Previous genon	ne-wide-si	Previous genome-wide-significant loci still reaching significance	till reaching sig	ınificance											
rs4844610	_	207802552	CR1	C/A	0.187	1.16	1.12-1.20	8.2×10^{-16}	1.20	1.13-1.27	3.8×10^{-10}	1.17	1.13-1.21	3.6×10^{-24}	$0, 8 \times 10^{-1}$
rs6733839	2	127892810	BIN1	C/T	0.407	1.18	1.15-1.22	4.0×10^{-28}	1.23	1.18-1.29	2.0×10^{-18}	1.20	1.17-1.23	2.1×10^{-44}	$15, 2 \times 10^{-1}$
rs10933431	2	233981912	INPP5D	5/C	0.223	06:0	0.87-0.94	2.6×10^{-7}	0.92	0.87-0.97	3.2×10^{-3}	0.91	0.88-0.94	3.4×10^{-9}	$0, 8 \times 10^{-1}$
rs9271058	9	32575406	HLA-DRB1	T/A	0.270	1.10	1.06-1.14	5.1×10^{-8}	1.11	1.06-1.17	5.7×10^{-5}	1.10	1.07-1.13	1.4×10^{-11}	$10, 3 \times 10^{-1}$
rs75932628	9	41129252	TREM2	C/T	0.008	2.01	1.65-2.44	2.9×10^{-12}	2.50	1.56-4.00	1.5×10 ⁻⁴	2.08	1.73-2.49	2.7×10^{-15}	$0, 6 \times 10^{-1}$
rs9473117	9	47431284	CD2AP	A/C	0.280	1.09	1.05-1.12	2.3×10^{-7}	1.11	1.05-1.16	1.0×10^{-4}	1.09	1.06-1.12	1.2×10^{-10}	$0, 6 \times 10^{-1}$
rs12539172	7	100091795	NYAP19	C/T	0.303	0.93	0.91-0.96	2.1×10^{-5}	0.89	0.84-0.93	2.1×10^{-6}	0.92	0.90-0.95	9.3×10^{-10}	$0, 8 \times 10^{-1}$
rs10808026	7	143099133	EPHA1	C/A	0.199	06:0	0.87-0.94	3.1×10^{-8}	0.91	96-0-98.0	1.1 × 10 ⁻³	06.0	0.88-0.93	1.3×10^{-10}	$0,5 \times 10^{-1}$
rs73223431	∞	27219987	PTK2B	C/T	0.367	1.10	1.07-1.13	8.3×10^{-10}	1.11	1.06-1.16	1.5×10^{-5}	1.10	1.07-1.13	6.3×10^{-14}	$0, 6 \times 10^{-1}$
rs9331896	8	27467686	CTO	1/C	0.387	0.88	0.85-0.91	3.6×10^{-16}	0.87	0.83-0.91	1.7×10^{-9}	0.88	0.85-0.90	4.6×10^{-24}	$3, 4 \times 10^{-1}$
rs3740688	Ħ	47380340	SP17h	1/6	0.448	0.91	0.89-0.94	9.7×10^{-11}	0.93	0.88-0.97	1.2×10^{-3}	0.92	0.89-0.94	5.4×10^{-13}	4, 4 × 10 ⁻¹
rs7933202	Ħ	59936926	MS4A2	A/C	0.391	0.89	0.86-0.92	2.2×10^{-15}	06.0	0.86-0.95	1.6×10^{-5}	0.89	0.87-0.92	1.9×10^{-19}	$27, 5 \times 10^{-2}$
rs3851179	Ħ	85868640	PICALM	C/T	0.356	0.89	0.86-0.91	5.8×10^{-16}	0.85	0.81-0.89	6.1×10^{-11}	0.88	0.86-0.90	6.0×10^{-25}	$0, 8 \times 10^{-1}$
rs11218343	Ħ	121435587	SORL1	1/C	0.040	0.81	0.76-0.88	2.7×10^{-8}	0.77	0.68-0.87	1.8×10^{-5}	0.80	0.75-0.85	2.9×10^{-12}	$7, 3 \times 10^{-1}$
rs17125924	4	53391680	FERMT2	A/G	0.093	1.13	1.08-1.19	6.6×10^{-7}	1.15	1.06-1.25	5.0×10^{-4}	1.14	1.09-1.18	1.4×10^{-9}	8, 3×10 ⁻¹
rs12881735	4	92932828	SLC24A4	1/C	0.221	0.92	0.88-0.95	4.9×10^{-7}	0.92	0.87-0.97	4.3×10^{-3}	0.92	0.89-0.94	7.4×10^{-9}	$0, 6 \times 10^{-1}$
rs3752246	19	1056492	ABCA7	D//2	0.182	1.13	1.09-1.18	6.6×10^{-10}	1.18	1.11-1.25	4.7×10^{-8}	1.15	1.11-1.18	3.1×10^{-16}	$0,5 \times 10^{-1}$
rs429358	19	45411941	APOE	1/C	0.216	3.32	3.20-3.45	1.2×10^{-881}	APOE r	egion not carr	region not carried forward to	replication stage	n stage		
rs6024870	20	54997568	CASS4	G/A	0.088	0.88	0.84-0.93	1.1 × 10 ⁻⁶	06.0	0.82-0.97	9.0×10^{-3}	0.88	0.85-0.92	3.5×10^{-8}	$0, 9 \times 10^{-1}$
New genome-wide-significant loci reaching significance	ide-signif	icant loci reach	ing significanc	jų.											
rs7920721	10	11720308	ECHDC3	A/G	0.389	1.08	1.05-1.11	1.9×10^{-7}	1.07	1.02-1.12	3.2×10^{-3}	1.08	1.05-1.11	2.3×10^{-9}	0.8×10^{-1}
rs138190086	17	61538148	ACE	G/A	0.020	1.29	1.15-1.44	7.5 ×10 ⁻⁶	1.41	1.18-1.69	1.8×10^{-4}	1.32	1.20-1.45	7.5×10^{-9}	$0, 9 \times 10^{-1}$
Previous genon	ne-wide-si	Previous genome-wide-significant loci not reaching significance	ot reaching sig	nificance											
rs190982	2	88223420	MEF2C	A/G	0.390	0.95	0.92-0.97	2.8×10^{-4}	0.93	0.89-0.98	2.7×10^{-3}	0.94	0.92-0.97	2.8 ×10 ⁻⁶	$0, 6 \times 10^{-1}$
1170077															

*Variants showing the best level of association after meta-analysis of Stages 1 and 2. *Build 37, assembly hg/9. 'Based on position of top SNP in reference to the RefSeq assembly. *Average in the discovery sample. *Calculated with respect to the minor allele. 'Cochran's Q test *Previously the ZWWPWI locus. *Previously the CELFI locus. Chr., chromosome; Cl, confidence interval; OR, odds ratio; P; heterogeneity estimate.

Stage 3A							Stage 1	Stage $1+2$ ($n=82,771$)	3	Stage	Stage 3A (n = 11,666)	(9:	Overal	Overall (n = 94,437)	
SNPa	Chr.	Position ^b	Closest gene	Major minor allele		MAFe	S.	95% CI [†]	ď	80	95% CI ^f	٩	S S	95% CI ^f	Meta P
rs4735340	8	95976251	NDUFAF6	T/A		0.476	0.94	0.92-0.96	3.4×10^{-7}	0.92	0.83-1.02	9.7×10^{-2} 0.94	-2 0.94	0.92-0.96	9.2 × 10 ⁻⁸
rs79207218	10	11720308	ECHDC3	A/G		0.390	1.08	1.05-1.11	2.3×10^{-9}	1.11	1.04-1.18	1.5×10^{-3} 1.08	3 1.08	1.06-1.11	1.8×10^{-11}
rs7295246	12	43967677	ADAMTS20	1/6		0.413	1.07	1.04-1.09	2.7×10^{-7}	1.02	0.96-1.09	4.5×10^{-1} 1.06	-1 1.06	1.04-1.08	3.9×10^{-7}
rs10467994	15	51008687	SPPL2A	1/C		0.333	0.94	0.91-0.96	3.9×10^{-7}	0.97	0.87-1.08	6.2×10^{-1}	-1 0.94	0.92-0.96	4.3×10^{-7}
rs593742	15	59045774	ADAM10	A/G		0.295	0.93	0.91-0.96	1.3×10^{-7}	0.91	0.85-0.98	1.5×10^{-2}	-2 0.93	0.91-0.95	6.8×10^{-9}
rs7185636	16	19808163	IQCK	1/C		0.180	0.92	0.89-0.95	8.4×10^{-8}	0.94	0.86-1.01	1.1×10^{-1}	0.92	0.89-0.95	2.4×10^{-8}
rs2632516	17	56409089	MIR142/TSPOAP1-AS1	1-AST" G/C		0.440	0.94	0.92-0.96	2.3×10^{-7}	0.91	0.82-1.01	7.5×10^{-2}	-2 0.94	0.91-0.96	5.3×10^{-8}
rs138190086	17	61538148	ACE	G/A		0.020	1.32	1.20-1.45	7.5×10^{-9}	1.17	0.92-1.48	2.1×10^{-1}	1.30	1.19-1.42	5.3×10^{-9}
rs2830500	21	28156856	ADAMTS1	C/A		0.308	0.93	0.91-0.96	7.4×10^{-8}	0.95	0.89-1.02	1.3×10^{-1}	1 0.93	0.91-0.96	2.6×10^{-8}
Stage 3B						Sta	age 1 (n =	Stage 1 ($n = 63,926$)		Stage 3B	Stage 3B $(n=30,511)^h$		Overall	Overall (n=94,437) ^h	
SNPª	Chr.	Position ^b	Closest gene ^c	Major/minor allele	MAF	F OR		95% CI ^f	Ь	OR	95% CI ^ŕ	Ь	OR	95% CI ^f	Meta P
rs71618613	2	29002985	SUCLG2P4	A/C	0.010	0.68		0.57-0.80	9.8 ×10 ⁻⁶	92.0	0.63-0.93	6.8×10^{-3}	0.71	0.63-0.81	3.3×10^{-7}
rs35868327	2	52665230	FST	T/A	0.013	13 0.69		0.59-0.80	7.8×10^{-7}	0.58	0.29-1.17	1.2×10^{-1}	0.68	0.59-0.79	2.6×10^{-7}
rs114812713	9	41034000	OARD1	g/C	0.030	30 1.35		1.24-1.47	4.5×10^{-12}	1.23	1.06-1.42	7.2×10^{-3}	1.32	1.22-1.42	2.1×10^{-13}
rs62039712	16	79355857	WWOX	G/A	0.116	5 1.17		1.10-1.23	1.2×10^{-7}	1.14	0.96-1.36	1.3 × 10 ⁻¹	1.16	1.10-1.23	3.7×10^{-8}
	-														

Novel loci were defined as loci not reported in Lambert et al. with (1) a Stage 1+2 meta P <5 x 10⁻² (nine variants after excluding TREM2) (Stage 3A) or (2) a MAF <0.05 and Stage 1 P <1 x 10⁻⁵ or MAF ≥ 0.05 and Stage 1 +2 meta P <5 x 10⁻² for genome regions not covered on the Stage 2 custom array (Stage 3B). ³SNPs showing the best level of association after meta-analysis of Stages 1, 2 and 3. ³Build 37, assembly Mg19. ³Based on position of top SNP in reference to the RefSeq assembly. ³Variant is annotated to both gene features. ³Average in the discovery sample. (Calculated with respect to the minor allele. ³Recently identified as a LOAD locus in two separate 2017 studies. ³Sample sizes for these loci are smaller (overall n = 89,769 for ST2, and n = 69,898 for WWOX).